PharmaResearch Balance Sheet Health
Financial Health criteria checks 6/6
PharmaResearch has a total shareholder equity of ₩462.2B and total debt of ₩33.3B, which brings its debt-to-equity ratio to 7.2%. Its total assets and total liabilities are ₩535.3B and ₩73.1B respectively. PharmaResearch's EBIT is ₩92.3B making its interest coverage ratio -20.9. It has cash and short-term investments of ₩160.3B.
Key information
7.2%
Debt to equity ratio
₩33.35b
Debt
| Interest coverage ratio | -20.9x |
| Cash | ₩160.30b |
| Equity | ₩462.19b |
| Total liabilities | ₩73.09b |
| Total assets | ₩535.28b |
Recent financial health updates
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08
Recent updates
PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25Financial Position Analysis
Short Term Liabilities: A214450's short term assets (₩256.5B) exceed its short term liabilities (₩65.9B).
Long Term Liabilities: A214450's short term assets (₩256.5B) exceed its long term liabilities (₩7.2B).
Debt to Equity History and Analysis
Debt Level: A214450 has more cash than its total debt.
Reducing Debt: A214450's debt to equity ratio has reduced from 9.3% to 7.2% over the past 5 years.
Debt Coverage: A214450's debt is well covered by operating cash flow (194.7%).
Interest Coverage: A214450 earns more interest than it pays, so coverage of interest payments is not a concern.